Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 29,494 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 29,494 shares of Liquidia stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $60.13, for a total transaction of $1,773,474.22. Following the sale, the director owned 38,755 shares of the company’s stock, valued at approximately $2,330,338.15. The trade was a 43.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded down $0.88 during trading on Tuesday, reaching $60.10. The company had a trading volume of 1,283,528 shares, compared to its average volume of 1,696,211. The company has a fifty day moving average of $42.53 and a two-hundred day moving average of $37.56. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $5.34 billion, a P/E ratio of 429.32 and a beta of 0.41. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $62.30.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s quarterly revenue was up 4187.1% compared to the same quarter last year. Equities research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LQDA shares. Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Wells Fargo & Company increased their price target on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. BTIG Research boosted their price objective on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Needham & Company LLC upped their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research report on Monday, May 11th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently bought and sold shares of the stock. Segall Bryant & Hamill LLC purchased a new position in shares of Liquidia in the first quarter worth $2,111,000. Bank of America Corp DE grew its holdings in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares during the last quarter. California State Teachers Retirement System grew its holdings in Liquidia by 25.0% in the 1st quarter. California State Teachers Retirement System now owns 72,438 shares of the company’s stock worth $2,734,000 after acquiring an additional 14,485 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Liquidia during the first quarter valued at about $3,650,000. Finally, Eversept Partners LP raised its stake in shares of Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after acquiring an additional 167,949 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).